Speaker:             David Rizzieri, MD

 Topic:                Journal Club:  Microtransplantation as consolidation for AML in first remission…

Guo M, Hu KX, Liu GX, et al.  HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia:  Long-term follow-up.  J Clin Oncol. 2012 Nov 20;30(33):4084-90. doi: 10.1200/JCO.2012.42.0281. Epub 2012 Oct 8.

Date:                          Tuesday, January 7, 2014

 Time:                         12:00 p.m. – 1:00 p.m.

Location:                  CR 9015 North Pavilion

Faculty (Speaker) Disclosure: David Rizzieri, M.D. has  indicated that he has the following relationships with industry to disclose:  Speaker for Allos, Celgene, Cephalon, Glaxo/Smith/Kline, Incyte, Novartis,  Sanofi Adventis , Seattle Genetics and Spectrum.  He is also a Principal Investigator for Bristol-Myers Squibb, Cyclacel, Eli Lilly, Micromet, Clavis, Sunesis and Supergen.  He is also an Advisory Board Member for Clavis and Novartis.  He is also a Consultant – Expert Reviewer for ODAC for CTI.  He is also an Expert Reviewer for DSMB Panel for Pfizer.

Activity Medical Director/Planning Committee Disclosure(s):  Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity:  Advisory Board Member for Genzyme; Principal Investigator for both Otsuka and Pfizer

Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)ä.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.  This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.